Ciclopiroxolamine: In vitro antifungal activity against clinical yeast isolates

International Journal of Antimicrobial Agents

Volumn 20, Issue 5, 2002, Pages 375-379

  Carrillo Muoz, A J ^a   Brio, S ^a   Alonso, R ^b   Del Valle, O ^c   Santos, P ^d   Quindos, G ^b  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

Antifungal; Candida; Ciclopiroxolamine; Clotrimazole; Econazole; Fluconazole; Itraconazole; Ketoconazole; Miconazole; NeoSensitabs; Nystatin; Susceptibility; Tioconazole

Indexed keywords

CICLOPIROXOLAMINE; CLOTRIMAZOLE; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; TIOCONAZOLE; ANTIFUNGAL AGENT; CICLOPIROX; PYRIDONE DERIVATIVE;

AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DOSE RESPONSE; FUNGAL STRAIN; FUNGUS ISOLATION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; COMPARATIVE STUDY; DRUG EFFECT; FUNGUS; HUMAN; MICROBIOLOGY; MYCOSIS;

ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MYCOSES; PYRIDONES;

EID: 0036846650     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00206-6     Document Type: Article

References (31)

1. Fromtling R.A. Overview of medically important azole derivatives. Clin. Microbiol. Rev. 1:1988;187-217.
2. Carrillo-Muñoz A.J., Pemán J., Gobernado M. Nuevos antifúngicos. Rev. Esp. Quimioter. 12:1999;181-204.
3. Carrillo-Muñoz A.J., Brió S., Quindós G. Una nueva generación de fármacos antifúngicos. Rev. Iberoam Micol. 18:2001;2-5.
4. Iwata K., Yamaguchi H. Studies on the mechanism of antifungal action of ciclopiroxolamine/inhibition of transmembrane transport of amino acid, K+ and phosphate in Candida albicans cells. Arzn Forch. 31:1981;1323-1327.
5. Abrams B.B., Hänel H., Hoehler T. Ciclopirox olamine: a hydroxypyridone antifungal agent. Clin. Dermatol. 9:1991;471-477.
6. Korting H.C., Grundmann-Kollmann M. The hydroxypyridones: a class of antimycotics of its own. Mycoses. 40:1997;243-247.
7. Braga P.C., Piatti G., Conti E., Vignali F. Effects of subinhibitory concentrations of ciclopirox in the adherence of Candida albicans to human bucal and vaginal cells. Arzn Forch. 42:1992;1368-1371.
8. Torres J.M. Ciclopiroxolamina. Un Nuevo antifúngico tópico, uso terapéutico. Drugs Today. 25:1989;1-17.
9. Harada I., Mitsui K., Uchida K., Yamaguchi H. In vitro antifungal activity of rilopirox, a new hydroxypyridone antimycotic agent. Jpn. J. Antibiot. 50:1997;195-199.
10. Rai M.K., Upadhyay S.K., Agrawal S.C. In vitro evaluation of three topical antimycotics against ring-worm fungi singly and in combination. Hind. Antibiot. Bull. 34:1992;104-107.
11. Hernández-Molina J.M., Llosa J., Martínez-Brocal A., de la Rosa L. Sensitivity of yeasts of the genus Candida to new antifungal agents. Enferm Infect. Microbiol. Clin. 9:1991;405-408.
12. Hanel H., Raether W., Dittmar W. Evaluation of fungicidal action in vitro and a skin model considering the influence of penetration kinetic various standard antimycotics. Ann. New York Acad. Sci. 544:1988;329-337.
13. Yamaguchi H., Uchida K., Hiratani T., et al. In vitro activity of ME1401, a new antifungal agent. Antimicrob. Angents Chemother. 30:1986;705-712.
14. Oliveri S., Cammarata E., Cappello G., Di Prima T., Fallica L., Panizza E. Ciclopiroxolamine: clinical and microbiological considerations. Preliminary data. Chimioterapia. 5:1986;23-25.
15. García-Figueroa R.G., Sauceda L., Ramírez-Palacios D., Cruz-Talonia F., Romero-Cabello R. Efectiveness and safety of ciclopiroxolamine 1% vaginal cream versus terconazole 0.8% vaginal cream the treatment of genital candidiasis. Ginecol. Obstet. Mex. 68:2000;154-159.
16. Giannoni M., Pollastro M., Jacobellis M. A clinical study of ciclopyroxolamine versus clotrimazole in the treatment of mycotic vulvovaginitis. Minerva Med. 81:1990;555-559.
17. Corte M., Jung K., Linker U., Martini H., Sapp-Boncelet I., Schulz M. Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor. Mycoses. 32:1989;200-203.
18. Lecha-Carralero V., Martínez-Tomás C. Experience in the treatment of skin mycoses with ciclopiroxolamine. Med. Cutanea Ibero Lat. Am. 17:1989;35-38.
19. Jue S.G., Dawson G.W., Brodgen R.N. Ciclopiroxolamine 1% cream. A preliminary review of antimicrobial activity and therapeutic use. Drugs. 29:1985;330-341.
20. Carrillo-Muñoz A.J., Torres-Rodríguez J.M. In vitro antifungal activity of sertaconazole, econazole and bifonazole against Candida spp. J. Antimicrob. Chemother. 36:1995;713-726.
21. Casals J.B. Tablet sensitivity testing of pathogenic fungi. J. Clin. Pathol. 32:1979;719-722.
22. Cantón E., Pemán J., Carrillo-Muñoz A.J., et al. Fluconazole susceptibilities of bloodstream Candida spp. isolates as determined by National Committee for Clinical Laboratory Standards Method M27-A and two other methods. J. Clin. Microbiol. 37:1999;2197-2200.
23. Carrillo-Muñoz A.J., Tur C., Estivill D., Montsant L., Torres-Rodríguez J.M. Evaluación de un método de difusión en agar para el estudio de la sensibilidad in vitro a los antifúngicos frente a cepas de referencia. Rev. Esp. Quimioter. 8:1995;221-228.
24. Carrillo-Muñoz A.J., Abarca L., Quindós G., et al. Multicenter evaluation of Neo-Sensitabs, a standardized diffusion method for yeast susceptibility testing. Rev. Iberoam Micol. 16:1999;92-96.
25. Martín-Mazuelos E., Aller A.I., Morilla D., Montero O. Antifungal activity of sertaconazole in vivo against clinical isolates of Candida spp. Chemotherapy. 42:1996;112-117.
26. Quindós G., Abarca L., Carrillo-Muñoz A.J., et al. Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev. Iberoam Micol. 16:1999;102-105.
27. Carrillo-Muñoz A.J., Tur-Tur C., Hernández-Molina J.M. Comparación de dos métodos para el estudio de la sensibilidad in vitro a sertaconazol en aislamientos clínicos de levaduras. Rev. Esp. Quimioter. 12:1999;58-63.
28. Carrillo-Muñoz A.J., Tur C., Torres J. In vitro antifungal activity of sertaconazole, bifonazole, ketoconazole and miconazole against yeasts of the Candida genus. J. Antimicrob. Chemother. 37:1996;815-819.
29. Sandven P. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test. J. Clin. Microbiol. 37:1999;3856-3859.
30. Troillet N., Durussel C., Bille J., Glausser M.P., Gham J.P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 12:1993;911-915.
31. Barry A.L., Brown S.D. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J. Clin. Microbiol. 34:(9):1996;2154-2157.